 - Eligible subjects are those whose unresectable, locally advanced andor metastatic colorectal cancer has progressed during or after receiving treatment with at least two, but not more than three, lines of therapy that collectively must have included at a minimum all of the following agents: 5-fluorouracil or capecitabine, irinotecan, and oxaliplatin unless, in the opinion of the investigator, the subject is not able to receive irinotecan andor oxaliplatin due to medical contraindications, in which case irinotecan andor oxaliplatin are not required to have been included in the prior lines of therapy. Adjuvant chemotherapy following definitive management of the primary lesion in the colon or rectum is allowed and will not be counted as a line of therapy. 